Table 3.
Distribution of cases by HER2 category, and by HER2 gene amplification status for the 2+ category
| ER‐neg/PR‐neg | ER‐neg/PR‐pos | Total ER‐neg | ER‐pos/PR‐neg | ER‐pos/PR‐pos | Total ER‐pos | Totals | |
|---|---|---|---|---|---|---|---|
| HER2 IHC status, n (%) | |||||||
| 0 | 4269 (36.7) | 235 (33.9) | 4504 (36.5) | 2725 (26.3) | 12 569 (30.2) | 15 294 (29.4) | 19 798 (30.8) |
| 1+ | 2183 (18.7) | 155 (22.4) | 2338 (18.9) | 2929 (28.2) | 15 434 (37.1) | 18 363 (35.3) | 20 701 (32.2) |
| 2+ | 1119 (9.6) | 63 (9.1) | 1182 (9.6) | 1502 (14.5) | 5621 (13.5) | 7123 (13.7) | 8305 (12.9) |
| 3+ | 2955 (25.4) | 177 (25.5) | 3132 (25.4) | 1719 (16.6) | 2368 (5.7) | 4087 (7.9) | 7219 (11.2) |
| Totals* | 11 645 (18.1*) | 693 (1.1*) | 12 338 (19.2*) | 10 377 (16.1*) | 41 613 (64.7*) | 51 990 (80.8*) | 64 328 (100.0*) |
| 2+ amplification status, n (%) | |||||||
| 2+ (non‐amplified) | 837 (74.8) | 49 (77.8) | 886 (75.0) | 1218 (81.1) | 4770 (84.9) | 5988 (84.1) | 5988 (72.1) |
| 2+ (amplified) | 282 (25.2) | 14 (22.2) | 296 (25.0) | 284 (18.9) | 851 (15.1) | 1135 (15.9) | 1135 (15.7) |
This analysis has been further categorised by ER and PR status (defined by final categorical result)
neg = negative, pos = positive.
*
Percentage figures shown for the totals are proportions of the total cases in the whole analysis.